Barecetamab

DB17479InvestigationalProtein Based Therapies

Barecetamab: Overview.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human epidermal growth factor receptor her3) (human monoclonal isu104 .gamma.1-chain), disulfide with human monoclonal isu104 .lambda.-chain, dimer
Code names: ISU-104

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Barecetamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.